mvf-her-2 (266-296)
Vaccineexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2011 (NCT01376505)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2Immunity, active
ERBB2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mvf-her-2 (266-296)
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06414733 | Phase 1 | Nov 1, 2024 | Indiana University |
| NCT01376505 | Phase 1 | Jun 1, 2011 | Ohio State University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Indiana University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Ohio State University | Academic/Hospital | 1 | 1 | 1 | 2011 |
2 organizations
Page 1 / 1